Bold Therapeutics Inc. company information, Employees & Contact Information

Bold Therapeutics Announces Presentation of Late-Breaking Data on BOLD-100's Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) PR Newswire

Bold Therapeutics Presents Late-Breaking Poster on BOLD-100's Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) at AACR Annual Meeting 2025 PR Newswire

Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight GlobeNewswire

Jasper Therapeutics Executives Make Bold Moves with Major Stock Purchases! TipRanks

Metastatic Colorectal Cancer Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential The Globe and Mail

FDA Grants Orphan Drug Status to BOLD-100 For the Treatment of Gastric Cancer Targeted Oncology

FDA Grants Orphan Drug Designation to BOLD-100 for Gastric Cancer OncLive

'My Time at Moffitt Was Instrumental' Moffitt

Bold Therapeutics to begin Phase Ib/IIa trial of GI cancer therapy in US Clinical Trials Arena

Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Biliary Tract and Gastric Cancers at ASCO 2024 PR Newswire

10 Promising Therapies for Hard-to-Treat Cancers BioSpace

Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound ACS Publications

Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug MedCity News

Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd Barchart.com

Jeff Marrazzo's Big, Bold Cell and Gene Therapy Vision Philadelphia Magazine

Bold Therapeutics Selected as a 2023 'Company to Watch' by Life Sciences British Columbia PR Newswire

Colorectal Cancer Clinical Trials Pipeline Analysis Featuring 125+ Key Companies by DelveInsight GlobeNewswire

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies PR Newswire

Gallant Therapeutics Raises Over $15 Million in Series A GlobeNewswire

Bold Therapeutics Successfully Completes Phase 1b Trial and Advances into Global Phase 2 Trial of BOLD-100 in the Treatment of Advanced GI Cancers PR Newswire

Meet Bold Health: Digital Therapeutics Startup Helping People Improve Digestive Health Forbes

BOLD Stock Price and Chart — NASDAQ:BOLD TradingView